
|Videos|May 16, 2017
Treating NSCLC Patients Without an Actionable Oncogenic Driver
Author(s)Sarah B. Goldberg, MD, MPH
Sarah B. Goldberg, MD, MPH, assistant professor of Medicine, Yale Cancer Center, discusses treating patients with non-small cell lung cancer (NSCLC) who do not have an actionable oncogenic driver.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
3
Imlunestrant Regimens Sustain Efficacy Benefit in ER+/HER2– Breast Cancer
4
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
5










































